NCT05933603View on ClinicalTrials.gov

Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 29, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Obstructive Sleep ApneaDown Syndrome
Interventions
DRUG

Atomoxetine and Oxybutynin (ato-oxy)

0.5 mg/kg atomoxetine (max 40 mg) and 5 mg oxybutynin by mouth nightly

Trial Locations (1)

86721

RECRUITING

University of Arizona, Tucson

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Arizona

OTHER